Ce diaporama a bien été signalé.
Le téléchargement de votre SlideShare est en cours. ×

Respiratory Syncytial Virus - RSV.pdf

Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Prochain SlideShare
Respiratory Syncytial Virus
Respiratory Syncytial Virus
Chargement dans…3
×

Consultez-les par la suite

1 sur 19 Publicité

Plus De Contenu Connexe

Plus par Dr. Fatma Ibrahim Abdel-latif Megahed (16)

Publicité

Plus récents (20)

Respiratory Syncytial Virus - RSV.pdf

  1. 1. Respiratory Syncytial Virus Infection Fatma Ibrahim Abdel-Latif Megahed Lecturer of family and community health nursing-Suez Canal University
  2. 2. Respiratory syncytial (sin-SISH-uhl) virus (RSV) is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. RSV spreads through contact with respiratory droplets (coughing, sneezing, or kissing) from an infected person or touching surfaces contaminated with the virus and then touching your eyes, nose, or mouth.
  3. 3. Each year, 4-5 million children younger than 4 years acquire an RSV infection, and more than 125,000 are hospitalized annually in the United States because of this infection. The impact of RSV infection is not limited to only young children. In United States, it is responsible for 177,000 hospitalizations and 14,000 deaths in the elderly ≥ 65 years of age.
  4. 4. It is a highly contagious, seasonal lung infection and is a common childhood illness that can affect adults too. Most children get the virus by 2 years of age. Most cases are mild, with cold-like symptoms. A severe infection leads to pneumonia and bronchiolitis.
  5. 5. Infants and adults who are at a higher risk of developing severe RSV include:  Premature infants.  Infants under 6 months of age.  Infants born with heart or lung conditions.  Children and adults with weakened immune systems (like after organ transplant or chemotherapy).  Children who have difficulty swallowing or can’t clear mucus.  Adults above age 65.  Adults with congestive heart failure, chronic obstructive pulmonary disease (COPD) or asthma.
  6. 6. Signs & Symptoms of RSV infection: Respiratory syncytial virus (RSV) causes acute respiratory tract illness in persons of all ages. The clinical manifestations vary with age, health status, and whether the infection is primary or secondary. Like the majority of other respiratory viruses [e.g. influenza (flu) or COVID-19], symptoms include runny nose, coughing, sneezing, fever, decreased appetite, and wheezing. The symptoms usually appear in stages. However, In very young infants, the only symptoms may be irritability, decreased activity, and breathing difficulties.
  7. 7. Signs & Symptoms of RSV infection cont.,: Those infected with RSV usually show symptoms within 4 to 6 days after getting infected. Healthy adults infected with RSV may have few symptoms but can still spread virus to others. Individuals infected with RSV are usually contagious for 3 to 8 days and recovery usually takes 1 to 2 weeks. However, some infants, and those with weakened immune systems, can continue to spread the virus even after they stop showing symptoms, for as long as 4 weeks.
  8. 8. Signs & Symptoms of RSV infection cont.,: RSV typically circulates with other seasonal respiratory viruses, like flu. However, the COVID-19 pandemic has impacted normal transmission patterns of RSV, leading recently to more unusual, “out of season” exposures and infections. Given its similarities in symptoms and co-circulation with other viral infections, the only way to determine if someone has an RSV infection is through clinical laboratory testing.
  9. 9. Some children with RSV may be at increased risk of developing a bacterial secondary infection, such as an ear infection. Call your doctor if your child has: o Symptoms that worsen or do not start to improve after 7 days. o A fever (with a rectal temperature of 100.4°F or higher) and they are younger than 3 months of age (12 weeks). o A fever that rises above 104°F repeatedly for a child of any age. o Poor sleep or fussiness, chest pain, ear tugging or ear drainage.
  10. 10. RSV has become a notifiable disease from 1 September 2022. A nasal swab test may be used (in serological tests) to determine if the child has RSV or another virus. A chest x-ray and/or oxygen saturation test may also be done to check for lung congestion.
  11. 11. RSV spreads just like a common-cold virus, from one person to another. It enters the body through the nose or eyes or, usually from: • Direct person-to-person contact with saliva, mucus, or nasal discharge. • Unclean hands (RSV can survive 30 minutes or more on unwashed hands). • Unclean objects or surfaces (RSV can survive up to 6 hours on surfaces, toys, keyboards, door knobs, … etc).
  12. 12. Most people's immune system will fight off the infection. Most symptoms are mild and can be managed with:  Bed rest.  Regular paracetamol and ibuprofen to relieve pain and fevers, if the child is uncomfortable.  Keeping hydrated with regular sips of water or frequent feeds for babies. Sometimes both children and older adults may need to be hospitalized and treated with intravenous fluids and extra oxygen. Antibiotics will not help the infection unless there is a secondary bacterial infection.
  13. 13. Prevention Tips:  Wash your hands more often with soap and water for at least 20 seconds, and help young children do the same.  Cover your coughs and sneezes with a tissue or your upper shirt sleeve, not your bare hands. Throw the tissue in the trash after use, and then wash your hands.  Avoid touching your eyes, nose, and mouth with unwashed hands.  Avoid close contact, such as kissing, or sharing cups or eating utensils, with sick people.  The virus can survive on surfaces or objects for about 4 to 7 hours. It is therefore important to clean and disinfect frequently touched surfaces, such as toys and doorknobs.
  14. 14. There is a monoclonal antibody treatment that may reduce the risk of severe RSV infection in some high-risk infants. Also, an antiviral drug called palivizumab (pah-lih-VIH- zu-mahb) is available to prevent severe RSV illness in high-risk infants (born prematurely or with congenital heart disease or chronic lung disease). However, the use of palivizumab is limited as it can only be used in certain children considered at high risk for complications, does not help cure or treat children already suffering from serious RSV disease, and cannot prevent RSV infection.
  15. 15. Sources: • https://www.nfid.org/infectious-diseases/rsv/ • https://my.clevelandclinic.org/health/diseases/8282- respiratory-syncytial-virus-in-children-and-adults • https://www.cdc.gov/dotw/rsv/index.html • https://www.healthychildren.org/English/health- issues/conditions/chest-lungs/Pages/RSV-When-Its- More-Than-Just-a-Cold.aspx • https://emedicine.medscape.com/article/971488- overview • https://www.health.nsw.gov.au/Infectious/factsheets/P ages/respiratory-syncytial-virus.aspx file:///C:/Users/FOX/Downloads/rsv-poster.pdf file:///C:/Users/FOX/Downloads/HHI171_Arabic.pdf

×